Phase 2 Colorectal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given written consent before any trial procedures begin (if someone is physically unable to sign, a trusted person of their choice may confirm consent in writing on their behalf)
• People with a confirmed diagnosis of adenocarcinoma of the colon, rectum, lower oesophagus, gastroesophageal junction, or stomach, based on tissue or cell testing
• People whose colorectal or gastroesophageal cancer has spread to other parts of the body (either at the time of first diagnosis or after)
• People who have at least one tumour that can be measured on scans, according to standard criteria
• People who have not yet received any treatment for their metastatic (spread) cancer
• People with a known enzyme deficiency called DPD deficiency, confirmed by a specific blood test showing elevated uracil levels (confirm with trial site for exact testing requirements)
• People aged 18 or older
• People who are reasonably active and able to care for themselves, with only mild limitations on physical activity (confirm with trial site)
• People whose bone marrow, kidney, and liver are functioning well enough, as shown by blood tests taken within 7 days before treatment starts — including adequate blood cell counts, kidney function, liver enzyme levels, and blood clotting measures (confirm with trial site for specific values)
• Women who could become pregnant must have a negative pregnancy blood test within 7 days before treatment starts
• Women who could become pregnant, and men, must agree to use effective contraception throughout the trial and for up to 7 months after treatment ends
• People who are willing and able to attend scheduled visits, follow the treatment plan, and complete required tests and procedures
• People who are affiliated with the Social Security System or an equivalent scheme

Who may not be able to join:

• People who have had a different type of cancer within the past 5 years, except for certain treated cancers such as cervical cancer in situ, non-melanoma skin cancer, or very early-stage bladder cancer
• People who have received radiotherapy within 28 days before the first dose of treatment
• People with certain active heart conditions, including moderate-to-severe heart failure, severe unstable chest pain (angina at rest), or a heart attack within the past 12 months
• People with high blood pressure that remains uncontrolled despite treatment
• People with an active infection of moderate severity or worse
• People with a known history of HIV infection
• People with chronic hepatitis B or C infection
• People who take medication to control seizures
• People with brain or meningeal (brain lining) tumours that are causing symptoms
• People who have had an organ transplant
• People with a known allergy or sensitivity to any of the study drugs or their ingredients
• People planned to receive oxaliplatin who already have nerve damage (numbness, tingling) beyond mild levels
• People planned to receive bevacizumab who have had major surgery, an open biopsy, or a significant injury within 28 days before the first dose
• People planned to receive bevacizumab who have a history of any bleeding disorder, or who have had a significant bleeding event within 4 weeks before starting treatment
• People planned to receive trastuzumab, panitumumab, or bevacizumab who have active lung inflammation (interstitial lung disease) with ongoing symptoms
• People who are unable to swallow oral (tablet/capsule) medication
• People with an uncontrolled condition that prevents proper absorption of food or medication
• People who are pregnant or breastfeeding
• People who are unable or unwilling to attend the required medical follow-up, for any geographic, personal, medical, or psychological reason, or for any reason the trial doctor believes would interfere with safe participation
• People who have taken part in another clinical trial using an investigational treatment within the past 30 days
• People who have a close personal or professional relationship with the trial site or investigator
• People who are under legal guardianship, protective custody, or who have limited or no legal capacity

Important: Always verify eligibility with the trial site directly before applying.